These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
989 related articles for article (PubMed ID: 28859947)
1. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Giugliano RP; Pedersen TR; Park JG; De Ferrari GM; Gaciong ZA; Ceska R; Toth K; Gouni-Berthold I; Lopez-Miranda J; Schiele F; Mach F; Ott BR; Kanevsky E; Pineda AL; Somaratne R; Wasserman SM; Keech AC; Sever PS; Sabatine MS; Lancet; 2017 Oct; 390(10106):1962-1971. PubMed ID: 28859947 [TBL] [Abstract][Full Text] [Related]
2. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Sabatine MS; Leiter LA; Wiviott SD; Giugliano RP; Deedwania P; De Ferrari GM; Murphy SA; Kuder JF; Gouni-Berthold I; Lewis BS; Handelsman Y; Pineda AL; Honarpour N; Keech AC; Sever PS; Pedersen TR Lancet Diabetes Endocrinol; 2017 Dec; 5(12):941-950. PubMed ID: 28927706 [TBL] [Abstract][Full Text] [Related]
3. Inflammatory and Cholesterol Risk in the FOURIER Trial. Bohula EA; Giugliano RP; Leiter LA; Verma S; Park JG; Sever PS; Lira Pineda A; Honarpour N; Wang H; Murphy SA; Keech A; Pedersen TR; Sabatine MS Circulation; 2018 Jul; 138(2):131-140. PubMed ID: 29530884 [TBL] [Abstract][Full Text] [Related]
4. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. Sabatine MS; Giugliano RP; Keech AC; Honarpour N; Wiviott SD; Murphy SA; Kuder JF; Wang H; Liu T; Wasserman SM; Sever PS; Pedersen TR; N Engl J Med; 2017 May; 376(18):1713-1722. PubMed ID: 28304224 [TBL] [Abstract][Full Text] [Related]
5. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial. Giugliano RP; Keech A; Murphy SA; Huber K; Tokgozoglu SL; Lewis BS; Ferreira J; Pineda AL; Somaratne R; Sever PS; Pedersen TR; Sabatine MS JAMA Cardiol; 2017 Dec; 2(12):1385-1391. PubMed ID: 29117276 [TBL] [Abstract][Full Text] [Related]
6. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Bonaca MP; Nault P; Giugliano RP; Keech AC; Pineda AL; Kanevsky E; Kuder J; Murphy SA; Jukema JW; Lewis BS; Tokgozoglu L; Somaratne R; Sever PS; Pedersen TR; Sabatine MS Circulation; 2018 Jan; 137(4):338-350. PubMed ID: 29133605 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Raal FJ; Honarpour N; Blom DJ; Hovingh GK; Xu F; Scott R; Wasserman SM; Stein EA; Lancet; 2015 Jan; 385(9965):341-50. PubMed ID: 25282520 [TBL] [Abstract][Full Text] [Related]
8. Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE. Gaba P; O'Donoghue ML; Park JG; Wiviott SD; Atar D; Kuder JF; Im K; Murphy SA; De Ferrari GM; Gaciong ZA; Toth K; Gouni-Berthold I; Lopez-Miranda J; Schiele F; Mach F; Flores-Arredondo JH; López JAG; Elliott-Davey M; Wang B; Monsalvo ML; Abbasi S; Giugliano RP; Sabatine MS Circulation; 2023 Apr; 147(16):1192-1203. PubMed ID: 36779348 [TBL] [Abstract][Full Text] [Related]
9. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. Raal FJ; Hovingh GK; Blom D; Santos RD; Harada-Shiba M; Bruckert E; Couture P; Soran H; Watts GF; Kurtz C; Honarpour N; Tang L; Kasichayanula S; Wasserman SM; Stein EA Lancet Diabetes Endocrinol; 2017 Apr; 5(4):280-290. PubMed ID: 28215937 [TBL] [Abstract][Full Text] [Related]
10. Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis. Giugliano RP; Pedersen TR; Saver JL; Sever PS; Keech AC; Bohula EA; Murphy SA; Wasserman SM; Honarpour N; Wang H; Lira Pineda A; Sabatine MS; Stroke; 2020 May; 51(5):1546-1554. PubMed ID: 32312223 [TBL] [Abstract][Full Text] [Related]
11. PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial. Koren MJ; Descamps O; Hata Y; Hengeveld EM; Hovingh GK; Ikonomidis I; Radu Juul Jensen MD; Langbakke IH; Martens FMAC; Søndergaard AL; Witkowski A; Koenig W Lancet Diabetes Endocrinol; 2024 Mar; 12(3):174-183. PubMed ID: 38310920 [TBL] [Abstract][Full Text] [Related]
12. Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER. Sabatine MS; De Ferrari GM; Giugliano RP; Huber K; Lewis BS; Ferreira J; Kuder JF; Murphy SA; Wiviott SD; Kurtz CE; Honarpour N; Keech AC; Sever PS; Pedersen TR Circulation; 2018 Aug; 138(8):756-766. PubMed ID: 29626068 [TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Koren MJ; Scott R; Kim JB; Knusel B; Liu T; Lei L; Bolognese M; Wasserman SM Lancet; 2012 Dec; 380(9858):1995-2006. PubMed ID: 23141812 [TBL] [Abstract][Full Text] [Related]
14. Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study. Koren MJ; Sabatine MS; Giugliano RP; Langslet G; Wiviott SD; Kassahun H; Ruzza A; Ma Y; Somaratne R; Raal FJ JAMA Cardiol; 2017 Jun; 2(6):598-607. PubMed ID: 28291870 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial. Charytan DM; Sabatine MS; Pedersen TR; Im K; Park JG; Pineda AL; Wasserman SM; Deedwania P; Olsson AG; Sever PS; Keech AC; Giugliano RP; J Am Coll Cardiol; 2019 Jun; 73(23):2961-2970. PubMed ID: 31196453 [TBL] [Abstract][Full Text] [Related]